688399.SH
Jiangsu Bioperfectus Technologies Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 23.26
+2.33%Oct 13, 2026, 12:32 UTC
Junkang Biotech’s 1.7451 million unrestricted shares in Shuoshi Bio were judicially frozen, representing 5.11% of its holdings and 1.41% of the company’s total shares.
Source:Oct 12, 2026, 12:19 UTC
China’s National Medical Products Administration issued Shuoshi Bio a Class III medical-device registration certificate for its HPV nucleic acid genotyping test kit.
Source:Oct 8, 2026, 14:35 UTC
Shuoshi Bio's board rejected the controlling shareholder's proposal to convene an extraordinary shareholders' meeting, with four votes in favor and five against.
Source:Oct 8, 2026, 14:12 UTC
The Shanghai Stock Exchange issued a regulatory work letter concerning board resolutions and other matters at Jiangsu Bioperfectus Technologies.
Source:Sep 21, 2026, 11:54 UTC
Fang Yongsheng's voting rights over SSBIO shares held via Taizhou Shuokang and Taizhou Shuoyuan fell from 32.24% to 28.43% after the two partnerships' executive partners changed and the concert party relationship was terminated; actual shareholdings were unchanged and the controlling shareholder and actual controller remained unchanged.
Source:Aug 27, 2026, 11:33 UTC
Suzhou Sursen Biopharmaceutical Co., Ltd. announced its 2026 first-half results: net profit attributable to shareholders was 19.5646 million yuan, up 390.02% year-on-year, with revenue of 147 million yuan, down 16.03%.
Source: